RVL Pharmaceuticals plc RVLPQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -20.81% | 9.09% | 20.38% | 46.94% | -- |
| Total Depreciation and Amortization | -13.38% | -91.14% | -95.41% | -96.95% | -- |
| Total Amortization of Deferred Charges | -74.44% | -44.23% | -0.16% | 65.41% | -- |
| Total Other Non-Cash Items | 2,231.13% | -64.81% | -5.48% | -98.59% | -- |
| Change in Net Operating Assets | -100.10% | 197.30% | 158.78% | 124.33% | -- |
| Cash from Operations | 13.94% | 46.30% | 30.92% | -18.61% | -- |
| Capital Expenditure | -648.18% | -46.29% | 57.80% | 92.51% | -- |
| Sale of Property, Plant, and Equipment | 497.48% | 641.94% | 875.56% | 900.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -- |
| Cash from Investing | -101.92% | -101.01% | -99.89% | -99.81% | -- |
| Total Debt Issued | -62.24% | -62.24% | -62.24% | -- | -- |
| Total Debt Repaid | 97.15% | 97.00% | 98.78% | 82.59% | -- |
| Issuance of Common Stock | -27.00% | -27.00% | -26.96% | 11,397.55% | -- |
| Repurchase of Common Stock | 60.26% | 62.86% | 79.05% | 96.28% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 129.14% | 127.78% | 130.87% | 149.73% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 88.59% | 107.60% | 105.57% | 143.66% | -- |